Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Takeda Pharmaceuticals U S A Inc. has 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This matter is handled by 1 distinct examiner, WHITEMAN, BRIAN A, who is the busiest examiner for the portfolio. The prosecution is localized within 1 distinct art unit, reflecting a highly focused point of interaction with the patent office.
With only 1 pending office action, the immediate prosecution risk is concentrated. WHITEMAN, BRIAN A is responsible for the 1 busiest examiner pending action, making their specific examination style the central factor for the company's current biotechnology filings. This lack of examiner diversity means the practitioner cannot compare different examiner responses within the current pending set to refine their approach.
The focus on 1 distinct art unit implies that the technical subject matter is currently confined to a specific regulatory or scientific niche. While this simplifies the technical expertise required for the current workload, it also means the portfolio's immediate progress depends entirely on the resolution of this single action. Practitioners should focus on the specific precedents and internal manuals relevant to this one art unit to move the 1 pending office action toward allowance.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WHITEMAN, BRIAN A | 1 | 68.5% | +16.7% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17998085 | METHODS FOR THE TREATMENT OF NUCLEOTIDE REPEAT EXPANSION DISORDERS ASSOCIATED WITH MSH3 ACTIVITY | WHITEMAN, BRIAN A | 58d overdue |
| Art Unit | Apps |
|---|---|
| 1636 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17998085 | METHODS FOR THE TREATMENT OF NUCLEOTIDE REPEAT EXPANSION DISORDERS ASSOCIATED WITH MSH3 ACTIVITY | WHITEMAN, BRIAN A | 1636 | §112 | Final Rejection | 58d overdue | Pending | Nov 07, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial